*ST长药
(300391)
| 流通市值：16.78亿 | | | 总市值：16.78亿 |
| 流通股本：3.50亿 | | | 总股本：3.50亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 103,683,885.34 | 111,625,132.67 | 101,004,271.66 | 73,653,692.97 |
| 营业收入 | 103,683,885.34 | 111,625,132.67 | 101,004,271.66 | 73,653,692.97 |
| 二、营业总成本 | 164,016,116.81 | 355,147,875.33 | 230,247,560.76 | 164,292,501.69 |
| 营业成本 | 105,389,197.67 | 118,791,058.48 | 96,028,186.66 | 69,482,031.98 |
| 税金及附加 | 614,069.95 | 2,474,641.66 | 2,009,584.06 | 1,249,862.54 |
| 销售费用 | 2,939,791.68 | 12,980,244.36 | 13,041,596.22 | 9,403,184.58 |
| 管理费用 | 19,053,546.04 | 102,594,239.69 | 52,775,025.94 | 33,608,935.27 |
| 研发费用 | 1,046,230.8 | 7,897,062.02 | 3,328,745.66 | 2,205,310.31 |
| 财务费用 | 34,973,280.67 | 110,410,629.12 | 63,064,422.22 | 48,343,177.01 |
| 其中:利息费用 | 35,220,018.1 | 111,173,734.74 | 61,345,196.06 | 48,874,983.65 |
| 其中:利息收入 | 3,009.72 | 61,300.42 | 584,041.47 | 44,262.3 |
| 加:公允价值变动收益 | - | 0 | - | - |
| 加:投资收益 | 2,900,000 | -4,391,497.52 | - | - |
| 资产处置收益 | -101,726.14 | -303,874.08 | -495,306.54 | -520,863.55 |
| 资产减值损失(新) | - | -448,552,187.19 | -27,392,907.64 | -27,294,182.41 |
| 信用减值损失(新) | -31,953,818.21 | -634,652,760.69 | -120,018,439.53 | -120,252,252.85 |
| 其他收益 | 315,367.93 | 627,652.88 | 520,871.33 | 346,793.85 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -89,172,407.89 | -1,330,795,409.26 | -276,629,071.48 | -238,359,313.68 |
| 加:营业外收入 | 65,209.47 | 148,503.87 | 30,216.67 | 8,064.67 |
| 减:营业外支出 | 289,356.56 | 97,068,868.66 | 3,499,794.72 | 3,353,913.44 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -89,396,554.98 | -1,427,715,774.05 | -280,098,649.53 | -241,705,162.45 |
| 减:所得税费用 | - | 10,960,677.8 | 6,526.35 | - |
| 六、净利润 | -89,396,554.98 | -1,438,676,451.85 | -280,105,175.88 | -241,705,162.45 |
| 持续经营净利润 | -89,396,554.98 | -1,438,676,451.85 | -280,105,175.88 | -241,705,162.45 |
| 归属于母公司股东的净利润 | -60,812,317.13 | -627,961,728.5 | -180,970,726.99 | -152,573,059.07 |
| 少数股东损益 | -28,584,237.85 | -810,714,723.35 | -99,134,448.89 | -89,132,103.38 |
| (一)基本每股收益 | -0.17 | -1.79 | -0.52 | -0.44 |
| (二)稀释每股收益 | -0.17 | -1.79 | -0.52 | -0.44 |
| 九、综合收益总额 | -89,396,554.98 | -1,438,676,451.85 | -280,105,175.88 | -241,705,162.45 |
| 归属于母公司股东的综合收益总额 | -60,812,317.13 | -627,961,728.5 | -180,970,726.99 | -152,573,059.07 |
| 归属于少数股东的综合收益总额 | -28,584,237.85 | -810,714,723.35 | -99,134,448.89 | -89,132,103.38 |
| 公告日期 | 2025-04-28 | 2025-04-21 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |